Oppenheimer assumes MediWound stock at outperform, sets $34 PT

© Eran Lavie, MediWound PR

On Monday, Oppenheimer analysts assumed coverage of MediWound Ltd (NASDAQ: MDWD) stock with an Outperform rating and set a price target of $34. This marks a slight adjustment from the previous target of $36 set by OPCO. According to InvestingPro data, analyst targets range from $25 to $39, with the stock showing strong momentum, gaining nearly 8% in the past week and 23% year-to-date.

The decision follows MediWound's recent update on its first-quarter 2025 performance, which highlighted progress in its clinical and commercial endeavors. While the company maintains a healthy balance sheet with more cash than debt and a current ratio of 2.15, InvestingPro analysis indicates it's not yet profitable, with an EBITDA of -$20.08M in the last twelve months. The company has initiated recruitment for the global EscharEx Phase 3 VALUE trial, with most U.S. sites operational and a target of 40 sites across the United States and Europe. Interim data from this trial is anticipated by mid-2026. Analysts consider the Phase 3 trial to be significantly derisked due to its design similarities with the Phase 2 trial.

MediWound's strategic collaborations with companies such as Solventum, Mölnlycke, and MIMEDX for venous leg ulcers (VLU), as well as with Coloplast (CSE:COLOb) and Kerecis for diabetic foot ulcers (DFU), were noted as validating the clinical and commercial potential of EscharEx. The company has also garnered enthusiasm from key opinion leaders at recent conferences. For deeper insights into MediWound's financial health and growth prospects, investors can access comprehensive analysis and 10+ additional ProTips through InvestingPro's detailed research reports.

Additionally, demand for MediWound's NexoBrid product continues to grow. The VLU Phase 2 head-to-head trial demonstrated that EscharEx was significantly more effective and achieved faster debridement compared to collagenase. The DFU Phase 2/3 trials are also making progress.

Oppenheimer's analysts have assumed coverage of MediWound with a positive outlook, reflecting confidence in the company's ongoing developments and strategic partnerships.

In other recent news, MediWound Ltd. reported its fourth-quarter 2024 earnings, surpassing expectations with an EPS of -0.36 against the projected -0.56. The company's revenue for the quarter reached $5.84 million, slightly above the forecast of $5.83 million, contributing to a total revenue of $20.2 million for the year 2024. H.C. Wainwright has responded to these developments by raising the price target for MediWound shares to $31 and maintaining a Buy rating, citing the progress of the company's clinical programs. MediWound is advancing its Phase 3 VALUE study, which evaluates EscharEx for venous leg ulcers, with interim analysis expected by mid-2026. Additionally, a Phase 2 study comparing EscharEx to collagenase products is set to begin in the latter half of 2025. A recent post hoc analysis published in the journal Wounds highlighted EscharEx's potential advantages over SANTYL, showing faster and more complete debridement of venous leg ulcers. The company is also preparing for a Phase 2/3 study for diabetic foot ulcers in 2026, supported by strategic research collaborations. MediWound's existing product, NexoBrid, continues to expand its market presence, with projected revenue growth in 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.